Abstract
The overexpression of the erbB-2 (HER-2, neu) gene has attracted significant interest as a molecular target for the rational design of cancer therapies. This review examines the design and preclinical testing phase for one such experimental therapy, recombinant toxins targeted to the erbB-2 protein, termed e23(Fv)PEs.
MeSH terms
-
ADP Ribose Transferases*
-
Animals
-
Antibodies
-
Antibody Formation
-
Bacterial Toxins / genetics
-
Drug Evaluation, Preclinical
-
Exotoxins / pharmacology
-
Humans
-
Immunotoxins / administration & dosage
-
Immunotoxins / immunology
-
Immunotoxins / pharmacology*
-
Immunotoxins / therapeutic use
-
Immunotoxins / toxicity
-
Macaca fascicularis
-
Mice
-
Neoplasms / drug therapy*
-
Pseudomonas aeruginosa / genetics
-
Pseudomonas aeruginosa Exotoxin A
-
Receptor, ErbB-2 / drug effects*
-
Receptor, ErbB-2 / immunology
-
Recombinant Fusion Proteins / therapeutic use
-
Recombinant Proteins / therapeutic use
-
Single-Chain Antibodies
-
Tumor Cells, Cultured
-
Virulence Factors*
Substances
-
Antibodies
-
Bacterial Toxins
-
Exotoxins
-
Immunotoxins
-
OLX 209
-
Recombinant Fusion Proteins
-
Recombinant Proteins
-
Single-Chain Antibodies
-
Virulence Factors
-
ADP Ribose Transferases
-
Receptor, ErbB-2